Pacritinib-d4

Pacritinib-d8 (SB1518-d8) is the deuterium labeled Pacritinib (HY-16379) . Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM) . Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM) .

Product Specifications

Product Name Alternative

SB1518-d4

UNSPSC

12352005

Target

FLT3; Isotope-Labeled Compounds; JAK

Related Pathways

Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Purity

98.42

Smiles

[2H]C(CCC1([2H])[2H])([2H])N1CCOC(C=C2)=C3COC/C=C/COCC4=CC=CC(C5=N/C(NC=C5)=N\C2=C3)=C4

Molecular Formula

C28H28D4N4O3

Molecular Weight

476.60

References & Citations

[1]William AD, et al. Discovery of the macrocycle 11- (2-pyrrolidin-1-yl-ethoxy) -14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6) .1 (8,12) ]heptacosa-1 (25),2 (26),3,5,8,10,12 (27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JA|[2]Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1 (11) :e44.|[3]Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25 (11) :1751-9.